Clene

Clene P/TBV

The Price to Tangible Book Value (P/TBV) of Clene (CLNN) as of Oct 18, 2026 is -2.83. In the previous year, Price to Tangible Book Value (P/TBV) was -5.63 — a change of -49.65% (higher).

P/TBV

-2.83

YoY

-49.65%

Last updated:

Price to Tangible Book Value (P/TBV) of Clene is 2025 -2.83 . Price to Tangible Book Value (P/TBV) of Clene was 2024 -5.63 . It decreases by -49.65% higher compared to the previous year.

The Clene P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
9.96 USD
Jan 1, 2019
10.19 USD
Jan 1, 2020
146.11 USD
Jan 1, 2021
3.96 USD
Jan 1, 2022
15.39 USD
Jan 1, 2023
3.72 USD
Jan 1, 2024
-5.63 USD
Jan 1, 2025
-2.83 USD
The Clene P/TBV history
YEARP/TBVYoY
-2.83-49.65%
-5.63-251.18%
3.72-75.83%
15.39+289.16%
3.96-97.29%
146.11+1,333.14%
10.19+2.31%
9.96—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clene Stock analysis

What does Clene do? Clene Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, operating within the health care sector and specifically in the biotechnology industry. The company went public via an IPO on August 27, 2018, and currently employs 75 full-time staff. Clene focuses on developing therapeutics for neurodegenerative diseases, with its primary drug candidate being CNM-Au8, an oral suspension of gold nanocrystals. The company's research targets energetic failure, an underlying factor in many neurological conditions, aiming to restore neuronal health and function by enhancing energy production and utilization. CNM-Au8 works through catalytically active nanocrystals that support cellular energy processes, promoting neuroprotection and remyelination by improving resilience to disease-related stressors. The company also has other product candidates, including CNM-ZnAg, a spectrum antiviral and antibacterial agent composed of zinc and silver ions, and CNM-AgZn17, a gel polymer suspension of zinc and silver designed for treating infectious diseases and supporting wound healing. Clene's website is https://clene.com/ and it is listed under the ticker CLNN with ISIN US1856342019. The company remains in the clinical development phase, focusing on advancing its pipeline of treatments for neurological and infectious conditions. Clene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clene stock

Price to Tangible Book Value (P/TBV) of Clene is -2.83 in 2025.

Price to Tangible Book Value (P/TBV) of Clene changed from -5.63 to -2.83, representing a -49.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) Clene since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s Clene with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Clene

All Key Metrics — Clene